Trial Profile
A Randomized Phase 2 Study of LY2157299 Versus LY2157299 - Sorafenib Combination Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 May 2021
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Apr 2021 Status changed from active, no longer recruiting to completed.
- 04 Feb 2021 Planned End Date changed from 31 Jan 2021 to 31 Mar 2021.
- 05 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Jan 2021.